Therapy News and Research

RSS

Understanding the phases and treatment options for Peyronie’s disease

The review article titled"Current insights and future directions in Peyronie's disease management: A narrative review", was published on November 12, 2024 in UroPrecision.

2 Apr 2025

HLA-DRB1 molecule can be a potential target in treating acute myeloid leukemia

One main goal of anti-cancer therapies is to kill tumor cells without affecting the surrounding normal cells.

1 Apr 2025

New drug restores vision by regenerating retinal nerves

Vision is one of the most crucial human senses, yet over 300 million people worldwide are at risk of vision loss due to various retinal diseases.

1 Apr 2025

Study links low LDL-C levels to reduced risk of dementia

People with low levels of low-density lipoprotein cholesterol (LDL-C) in their blood have a lower risk of dementia, including lower risk of Alzheimer's disease related dementia, shows a study published online today in the Journal of Neurology Neurosurgery & Psychiatry.

1 Apr 2025

Scientists make breakthrough in understanding the causes of spina bifida

Scientists at Rady Children's Institute for Genomic Medicine, and the Department of Neurosciences and Pediatrics at the University of California, San Diego, have made a significant breakthrough in understanding the causes of spina bifida, a serious birth defect affecting thousands of newborns each year.

1 Apr 2025

Comprehensive AAV delivery map aids in advancing gene therapy

Gene therapy, a technique that is revolutionizing the treatment of multiple genetic conditions, including eye and muscle diseases and blood disorders, requires efficient and specific delivery of the genetic material to the tissue and cell type of interest.

1 Apr 2025

Emotional fear acts as a barrier to constructive communication among partners with PTSD

People with post-traumatic stress disorder (PTSD) symptoms often have trouble communicating and resolving relationship difficulties with their romantic partners, according to previous research by Steffany Fredman, associate professor of human development and family studies at Penn State, and others.

1 Apr 2025

NIH funds research to develop a game-changing HIV diagnostic tool

As of the end of 2023, nearly 40 million people worldwide were living with HIV, including approximately 1.2 million in the United States.

1 Apr 2025

The evolution of OCT for retinal imaging and disease intervention

Dr. Yifan Jian explores the evolution of OCT, challenges in retinal imaging, and AI's potential in biophotonics, shaping the future of ophthalmic diagnostics.

From Avantier Inc. 1 Apr 2025

Study links linoleic acid to triple-negative breast cancer growth

Linoleic acid, an omega-6 fatty acid found in seed oils such as soybean and safflower oil, and animal products including pork and eggs, specifically enhances the growth of the hard-to-treat "triple negative" breast cancer subtype, according to a preclinical study led by Weill Cornell Medicine investigators.

1 Apr 2025

New TIL therapy improves treatment's effectiveness in patients with metastatic gastrointestinal cancers

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment's effectiveness in patients with metastatic gastrointestinal cancers, according to results of a clinical trial led by researchers at the National Institutes of Health (NIH).

1 Apr 2025

New tool helps predict CAR T therapy outcomes for lymphoma patients

Researchers with City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, with its National Medical Center in Los Angeles ranked among the nation's top 5 cancer centers by U.S. News & World Report, and MSK have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient's likely response to chimeric antigen receptor (CAR) T cell therapy before starting the treatment, according to study results published today in Nature Medicine.

1 Apr 2025

WINREVAIR™ (sotatercept-csrk) reduced the risk of a composite of all-cause death, lung transplantation and hospitalization for pulmonary arterial hypertension (PAH) by 76% compared to placebo in the phase 3 ZENITH trial

Merck, known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR™ (sotatercept-csrk) compared to placebo in adults with pulmonary arterial hypertension (PAH, Group 1 PH) WHO* functional class (FC) III or IV at high risk of mortality who were on maximum tolerated background PAH therapy. At a median follow-up of 10.6 months (range, 0.3-26.1), WINREVAIR reduced the relative risk of major morbidity and mortality events (the composite of all-cause death, lung transplantation and PAH worsening-related hospitalization of ≥24 hours) by 76% (HR=0.24 [95% CI, 0.13-0.43]; p<0.0001 [1-sided]) compared to placebo.

1 Apr 2025

Research challenges traditional oxygen practices in trauma care

When a critically injured patient is admitted to the hospital, how much supplemental oxygen should they receive? New research published this week in JAMA Network Open led by investigators at the University of Colorado School of Medicine suggests it's often less than the current standard.

31 Mar 2025

Blood test offers insight into Alzheimer's stage and severity

A newly developed blood test for Alzheimer's disease not only aids in the diagnosis of the neurodegenerative condition but also indicates how far it has progressed, according to a study by researchers at Washington University School of Medicine in St. Louis and Lund University in Sweden.

31 Mar 2025

Embolic protection device does not reduce stroke rate in TAVR procedure

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the rate of stroke, according to a randomized trial presented at the American College of Cardiology's Annual Scientific Session.

31 Mar 2025

$Intravenous iron shows promise for heart failure with reduced ejection fraction$

Intravenous iron shows promise for heart failure with reduced ejection fraction

Among iron-deficient patients with heart failure with reduced ejection fraction (HFrEF), receiving intravenous iron supplementation was found to be safe but resulted in mixed findings, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.25).

31 Mar 2025

Study finds no benefit of early IABP use in cardiogenic shock patients

Compared with standard medical care, early use of a temporary intra-aortic balloon pump (IABP) to support heart function in patients who were critically ill with cardiogenic shock caused by heart failure did not improve 60-day survival or enable more patients to successfully transition to long-term treatment, according to featured clinical research presented at the American College of Cardiology's Annual Scientific Session (ACC.25) and simultaneously published in JACC

31 Mar 2025

Traditional Chinese medicine targets cholesterol metabolism for cancer treatment

Researchers explore how natural compounds in traditional Chinese medicine can modulate cholesterol metabolism to combat cancer.

31 Mar 2025

FAME-3 study reveals similar outcomes for CABG and PCI in severe triple-vessel heart disease

In sharp contrast to earlier studies, patients with severe triple-vessel heart disease fared equally well whether they underwent open-heart bypass surgery (CABG) or a less invasive procedure called PCI (percutaneous coronary intervention) at five years of follow-up, according to research presented at the American College of Cardiology's Annual Scientific Session.

31 Mar 2025